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Abstract	
	
Peritoneal	 dialysis	 (PD)	 is	 a	 life-saving	 form	 of	 renal	 replacement	 therapy	 for	 those	
with	End	Stage	Kidney	Disease.	Mesothelial	Cells	 (MC)	 line	 the	peritoneal	 cavity	 and	
help	 define	 peritoneal	 response	 to	 treatment-associated	 injury,	 a	 major	 reason	 for	
treatment	 failure.	 MicroRNAs	 (miRNAs)	 are	 important	 regulators	 but	 their	 roles	 in	
peritoneal	fibrosis	are	largely	unknown.	
In	this	study	microRNA-21	(miR-21)	was	one	of	the	most	abundant	miRNAs	in	primary	
MCs,	 and	 was	 up	 regulated	 by	 the	 profibrotic	 cytokine	 TGF-β1	 and	 in	 PD	 effluent-
derived	MCs	exhibiting	mesenchymal	phenotypic	change.	Increased	miR-21	was	found	
in	peritoneal	membrane	biopsies	from	PD	patients	compared	to	healthy	controls	 (PD	
biocompatible,	5.86x,	p=0.0001;	PD	conventional,	7.09x,	p<0.0001,	n=11	per	group).	In	
PD	effluent	 from	a	 cohort	of	 230	patients,	miR-21	was	higher	 in	 those	 receiving	 the	
therapy	 long-term	 compared	 to	 new	 starters	 (n=230,	 miR-21	 3.26x,	 p=0.001)	 and	
associated	with	 Icodextrin	usage	R=0.52, (0.20,	0.84),	peritonitis	count	R=0.16,	 (0.03,	
0.29)	 and	 dialysate	 cytokines.	 MiR-21	 down-regulated	 Programmed	 Cell	 Death	 4	
(PDCD4)	and	PDCD4	protein	was	decreased	in	peritoneal	membrane	biopsies	from	PD	
patients	compared	to	healthy	controls.	New	miR-21	targets	were	 identified	that	may	
be	important	during	peritoneal	dialysis	fibrogenesis.	These	data	identify	miR-21	as	an	
important	effector	of	fibrosis	in	the	peritoneal	membrane,	and	a	promising	biomarker	
in	the	dialysis	effluent	for	membrane	change	in	patients	receiving	PD.	
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Introduction	
	
End	stage	kidney	disease	means	that	650,000	people	in	The	United	States	depend	on	
renal	replacement	therapy	to	keep	them	alive,	a	number	increasing	by	5-8%	per	year.	
Dialysis	 treatment	 accounts	 for	 1-2%	 of	 national	 healthcare	 budgets,	 and	 may	 be	
provided	by	hemodialysis,	in	which	the	blood	is	purified	across	an	artificial	membrane,	
or	 by	 peritoneal	 dialysis	 (PD).	 In	 PD,	 exchange	 between	 the	 blood	 and	 the	 dialysate	
instilled	in	the	patient’s	own	peritoneal	cavity	occurs	across	the	peritoneal	membrane.	
Thus,	PD	 leads	to	constant	exposure	of	the	peritoneal	membrane	to	bioincompatible	
PD	solutions	and	a	basal	inflammatory	state,	resulting	in	membrane	damage	that	may	
progress	 to	 treatment	 failure1.	 Alterations	 in	 mesothelial	 cell	 (MC)	 phenotype,	
including	 acquisition	 of	 a	mesenchymal	 phenotype	 and	mesothelial	 cell	 loss,	 are	 an	
important	 determinant	 of	 these	 sequelae2,	 leading	 to	 increased	 synthesis	 of	
extracellular	matrix	components	and	release	of	pro-inflammatory	and	pro-angiogenic	
factors3.	MCs	 are	 also	 detectable	 in	 the	 spent	 dialysate,	 and	 acquire	 a	 progressively	
non-epithelioid	phenotype	with	longer	duration	dialysis4.	Cells	in	the	deeper	layers	of	
the	peritoneal	 tissue,	 including	the	stromal	 fibroblast	population,	may	also	make	key	
contributions	to	fibrogenesis5.	
	
Induction	of	in	vitro	and	in	vivo	mesenchymal	trans-differentiation	by	TGF-β1	has	been	
well	documented	in	the	peritoneal	membrane	and	other	tissues	and	organs3,	6,	7.	TGF-
β1	overexpression	 induces	structural	and	functional	membrane	alterations	 in	rat	and	
mouse	 peritoneum7,	 8	 and	 intra-peritoneal	 inhibition	 of	 TGF-β1	 preserves	 peritoneal	
morphology	and	function	in	this	model3.	TGF-β1-driven	phenotypic	change	in	primary	
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MCs	 is	 therefore	 a	 valuable	 model	 to	 study	 mechanisms	 of	 peritoneal	 fibrosis	
progression	associated	with	PD	therapy9.	
	
MicroRNAs	(miRNAs)	are	short,	non-coding	RNAs	that	regulate	gene	expression	at	the	
post-transcriptional	 level.	 One	 miRNA	 may	 regulate	 the	 expression	 of	 hundreds	 of	
target	mRNAs,	profoundly	affecting	cell	phenotype	and	function.	Alterations	in	miRNA	
expression	 have	 been	 described	 in	 a	 wide	 range	 of	 in	 vitro	 and	 in	 vivo	 models10.	
Studies	 on	 miRNA	 expression	 in	 different	 model	 systems	 and	 body	 fluids	 have	
emphasized	 their	 potential	 as	 therapeutic	 targets	 and	 disease	 biomarkers11-14.	
Mesothelial	cell	miRNA	expression,	function,	and	role	of	miRNAs	in	peritoneal	fibrosis	
are	 largely	 unknown,	 and	 recent	 studies	 have	begun	 to	 address	 this	 (reviewed	 in15).	
Quantification	of	7	miRNAs	 in	PDE-derived	cells	 from	28	prevalent	PD	patients	found	
correlation	with	peritoneal	transport	characteristics16.	Enforced	expression	of	miR-29b	
inhibited	 peritoneal	 fibrosis	 in	 a	 mouse	 model	 of	 daily	 intraperitoneal	 PD	 fluid	
infusion2.	MiR-30a	was	down	regulated	 in	a	 rat	PD	 infusion	model,	and	decreased	 in	
peritoneal	membrane	 from	 10	 established	 PD	 patients17.	 In	 this	 last	 study,	miR-30a	
targeted	 Snail,	 a	 key	 regulator	 of	mesothelial	 to	mesenchymal	 transition	 (MMT)	 via	
down-regulation	of	adherens	(E-cadherin)	and	tight	junctions	(Claudin-1,	Occludin	and	
ZO-1)18,	 19.	 MiR-589	 was	 down-regulated	 in	 6	 PD	 patients	 treated	 for	 more	 than	 6	
months20	 and	 miR-200c	 was	 down-regulated	 in	 PDE-derived	 cells	 from	 16	 patients	
undergoing	 PD	 for	more	 than	 6	months21.	 Collectively,	 these	 studies	 are	 suggestive	
that	 miRNAs	 are	 important	 regulators	 of	 MC	 phenotype	 and	 fibrogenesis	 in	 PD	
patients.	Measurement	of	miRNAs	in	PDE	may,	therefore,	be	valuable	in	predicting	the	
clinical	 course.	 However,	 this	 previous	 research	 has	 largely	 taken	 a	 literature-based	
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candidate	miRNA	approach,	and	drawn	conclusions	from	analyses	of	small	numbers	of	
patient-derived	samples.		
	
In	 this	 study,	miRNAs	were	 studied	 in	mesothelial	 cells	 cultured	 in	 vitro	 and	ex	 vivo	
from	 peritoneal	 dialysis	 patients,	 and	 linked	 to	 measurements	 conducted	 in	 the	
peritoneal	 dialysis	 effluent	 and	 the	peritoneal	membrane	 itself,	 to	provide	definitive	
identification	 of	 microRNAs	 expressed	 by	 MC’s	 and	 changes	 occurring	 as	 a	
consequence	of	peritoneal	dialysis,	and	to	link	these	to	likely	microRNA	functions.	MC	
miRNA	 profiles	 and	 responses	 to	 TGF-β1	 were	 characterized	 in	 vitro,	 and	 increased	
miR-21	was	demonstrated	in	MCs	incubated	with	TGF-β1,	and	in	separate	experiments	
in	 MCs	 exhibiting	 a	 mesenchymal	 phenotype	 derived	 from	 PDE.	 In	 a	 study	 of	 44	
peritoneal	membrane	biopsies,	 increased	miR-21	was	 found	 in	peritoneal	membrane	
from	PD	patients	compared	with	healthy	and	uremic	controls.	In	PDE	from	a	cohort	of	
230	 patients	 taken	 from	 The	 Global	 Fluid	 Study,	 miR-21	 associated	 with	 clinical	
parameters	 indicative	of	membrane	change	and	treatment	failure.	Analysis	of	miRNA	
targets	 identified	 miR-21	 regulation	 of	 tumor	 suppressor	 programmed	 cell	 death	 4	
(PDCD4)	 in	MCs	and	 in	peritoneal	membrane	biopsies	 from	PD	patients.	Finally,	 four	
previously	 unreported	 miR-21	 targets	 were	 identified,	 linked	 to	 the	 mesothelial	 to	
mesenchymal	process	occurring	as	a	consequence	of	PD	treatment.	
	
	
Materials	and	Methods	
	
Cell	culture,	TGF-β1	treatment	and	Cell	Transfection	
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Appropriate	 ethical	 approval	 was	 in	 place	 for	 all	 experiments	 involving	 specimens	
derived	 from	 patients,	 and	 all	 patients	 gave	 informed	 consent	 for	 use	 of	 their	
specimens	 for	 research	 purposes.	Human	peritoneal	mesothelial	 cells	 (HPMCs)	were	
obtained	 from	 enzymatically	 degraded	 specimens	 of	 human	 omentum	 as	 previously	
reported22.	 In	 brief,	 specimens	 of	 omentum	 from	 patients	 undergoing	 abdominal	
surgery	were	washed	in	PBS	before	incubation	with	0.125%	(w/v)	trypsin,	0.01%	(w/v)	
EDTA	 and	 0.1%	 (w/v)	 glucose	 for	 20	 mins	 at	 37oC	 with	 continuous	 rotation.	 After	
incubation	the	suspension	was	centrifuged	at	50x	g	 for	5	mins	at	4oC.	The	cell	pellet	
was	washed	once	in	culture	medium,	then	resuspended	in	culture	medium	and	seeded	
in	tissue	culture	flasks.	For	ex	vivo	analysis,	mesothelial	cells	derived	from	PD	patients’	
effluents	were	cultured	and	analyzed	as	described4.	 In	brief,	Human	mesothelial	cells	
from	 peritoneal	 dialysis	 effluent	 were	 obtained	 by	 centrifugation	 and	 passaged	 in	
culture	 two	 times	 at	 10	 to	 15	 day	 intervals.	 Morphologic	 features	 of	 cells	 were	
compared	and	remained	stable	through	passage.	Mesothelial	cells	were	characterized	
as	of	epithelial	or	fibroblast-like	character	as	previously	reported4.	
For	 microRNA	 gain-	 and	 loss-of	 function	 experiments,	 mirVana	 miRNA	 mimic	 and	
mirVana	miRNA	inhibitors	were	used	at	concentrations	of	5	pM,	10	pM	and	20	pM	for	
target	mRNA	measurements	 48	h	 after	 transfection.	 5	 pM	of	mirVana	miRNA	mimic	
were	used	for	protein	quantification	72	h	after	transfection.		
	
Peritoneal	Membrane	Study	
FFPE	peritoneal	membrane	samples	 from	44	pediatric	patients	 (1.83-19.16	years	old)	
included	 in	 the	 International	 Pediatric	 PD	 Biopsy	 Study	 were	 used	 in	 this	 analysis	
(www.clinicaltrials.gov,	 NCT01893710).	 Patients	 were	 matched	 for	 age,	 sex,	 PD	
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duration	 and	 submesothelial	 thickness.	 Patients	 with	 previous	 peritonitis,	 systemic	
diseases	 and	 abdominal	 surgery	 other	 than	 Tenckhoff	 catheter	 insertion,	 revision	 or	
kidney	 transplantation	 were	 excluded.	 Comprehensive	 individual	 clinical	 data	 were	
collected	 and	 assessed	 before	 analysis	 to	 exclude	 disparity	 regarding	 disease	
susceptibility	or	comorbidity.	Approval	was	obtained	from	local	ethics	committees,	and	
written	 informed	 consent	 obtained	 from	 patient	 and	 parents.	 FFPE	 samples	 were	
cresyl	 violet	 stained	 and	 the	 mesothelial	 and	 submesothelial	 compact	 zone	 were	
manually	micro	dissected	from	a	total	of	40	μm	section	using	a	Leica	RM	2165	rotary	
sliding	microtome	and	a	Leica	S8	APO	stereo	microscope.				
	
PD	Effluent	Study	
The	 Global	 Fluid	 Study	 is	 an	 international,	 multicenter,	 prospective,	 observational	
cohort	study	of	959	patients24.	Samples	from	a	single	center	were	used	for	microRNA	
analysis,	 to	 exclude	 center	 effects,	 and	 the	 first	 sample	 collected	 from	 each	 patient	
was	 analyzed.	 Dialysate	 cytokine	 levels	 had	 been	 measured	 previously	 by	
electrochemiluminescence24.	4-hour	dwell	dialysate	samples	were	stored	at	-80°C	and	
thawed	on	ice.	600	μl	aliquots	were	centrifuged	at	12,000g	at	4°C	for	20	min	prior	RNA	
extraction.	Extreme	outliers	(3)	were	re-tested	and	then	excluded,	as	the	results	from	
these	 samples	 showed	 high	 variance,	 consistent	 with	 sample	 degradation	 prior	 to	
analysis.	
	
RNA	isolation	
For	 RT-qPCR	 analysis,	 miRNA	 and	 mRNA	 arrays	 HPMCs	 were	 lysed	 in	 TRI	 reagent	
(Ambion,	 Life	 Technologies),	 and	 RNA	 was	 extracted	 as	 recommended	 by	 the	
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manufacturer.	RNA	from	PDE	was	isolated	from	500	μl	of	fluid	using	the	mirVana	PARIS	
Kit	(Ambion,	Life	Technologies).	To	monitor	extraction	efficacy,	0.5	pmol	of	cel-miR-39	
(Life	 Technologies,	 MC10956)	 was	 spiked-in	 to	 all	 PDE	 samples	 after	 addition	 of	 2x	
denaturing	 solution.	 Formalin-fixed,	 paraffin-embedded	 (FFPE)	 samples	 were	
processed	 immediately	after	sectioning	using	RecoverAllTM	total	nucleic	acid	 isolation	
kit	 (Ambion,	Life	Technologies)	according	 to	 the	manufacturer’s	 recommendations.	1	
μg	 of	 MS2	 RNA	 carrier	 (Roche)	 was	 added	 to	 biopsy	 extractions,	 to	 improve	 RNA	
recovery.		
	
Reverse	Transcriptase-quantitative	Polymerase	Chain	Reaction	(RT-qPCR)	Analysis	
cDNA	was	 synthesized	 from	2	μg	of	 total	RNA	using	 the	High	Capacity	 cDNA	reverse	
transcription	 kit	 (Life	 Technologies).	 Alternatively,	 10	 ng	 of	 total	 RNA	were	 used	 for	
cellular	miRNAs.	For	PDE	and	FFPE	samples,	constant	volumes	of	RNA	were	used.	RT-
qPCR	was	carried	out	 in	a	ViiATM	7	Real-Time	PCR	System	(Applied	Biosystems)	using	
Power	SYBR	Green	PCR	master	mix	(Applied	Biosystems).	The	primers	used	are	shown	
in	Table	1.	Taqman	Universal	Master	Mix	II	 (Applied	Biosystems)	and	specific	primers	
for	miR-21	and	miR-191	(Applied	Biosystems)	were	used	for	miRNA	analysis25.	mRNA	
and	 miRNA	 expression	 were	 normalized	 to	 GAPDH	 and	 miR-191	 respectively.	 The	
relative	changes	in	gene	expression	were	analyzed	by	the	2-ΔΔCt	method26.		
	
miRNA	and	mRNA	microarrays	
Microarray	assays	were	performed	on	HPMCs	derived	from	four	independent	donors.	
miRNA	 expression	 was	 measured	 in	 control	 samples	 and	 after	 1	 ng/ml	 of	 TGF-β1	
treatment	 for	 48	 h3,	 27-30.	 Confirmed	 in	 all	 samples	 by	 analysis	 of	 eight	 molecular	
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markers	chosen	as	indicators	of	epithelial	(E-Cadherin,	ZO-1,	Claudin	and	Occludin)	and	
mesenchymal	(Fibronectin,	Collagen	I,	Snail	and	α-SMA)	phenotype	(unpublished	data	
and3,	 27-30).	 A	 total	 of	 1	μg	 in	 a	 volume	of	 ≤2	μl	 of	 total	 RNA	 from	each	 sample	was	
subsequently	used	for	Toray	microarray	analysis,	performed	by	Central	Biotechnology	
Services	at	Cardiff	University	as	described	previously31.	For	ex	vivo	mRNA	microarray	
analysis	patient	derived	MCs	samples	were	classified	as:	E	phenotype	(9	samples)	and	
NE	 phenotype	 (8	 samples)30.	 Four	 omentum-derived	 MC	 samples	 were	 taken	 as	
controls.	Label	dye-swap	design	was	used	 in	these	experiments	using	the	Quick	Amp	
Labeling	 Kit,	 two-color	 (Agilent	 Technologies,	 Santa	 Clara,	 California,	 USA).	 mRNA	
microarray	analysis	was	carried	out	using	the	Whole	Human	Genome	Microarrays	Kit	
4x44	K	(Agilent	Technologies)	according	to	the	manufacturer’s	 instructions:	825	ng	of	
cRNA	 (Cy3-cRNA	 and	 Cy5-cRNA)	 were	 incubated	 with	 blocking	 agent	 and	
fragmentation	buffer,	30	minutes,	60°C.	Hybridization	was	performed	in	hybridization	
buffer	 at	 65°C	 for	 17	 hours	 in	 darkness	 and	 stirring	 at	 10	 rpm.	 Subsequently,	 slides	
were	introduced	in	different	saline	buffer	stringencies,	stabilization	solution	and	dried	
as	indicated	by	Agilent	Technologies.	Arrays	were	scanned	on	the	Agilent	Technologies	
G2505B	Micro	Array	Scanner	at	5	nm	resolution.	
	
Immunoblotting	
Whole	 cell	 protein	 samples	 were	 collected	 using	 RIPA	 Lysis	 Buffer	 (Santa	 Cruz	
Biotechnology,	 sc-24948)	 and	 protein	 concentrations	were	 determined	 using	 BioRad	
Protein	Assay	(BioRad,	5000001).	15	µg	of	protein	in	3x	Reducing	Loading	Buffer	were	
heated	 at	 95°C	 for	 five	 minutes,	 ice-cooled,	 separated	 by	 7.5%	 SDS-PAGE	 and	
transferred	onto	nitrocellulose	membranes	which	were	subsequently	blocked	using	5%	
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BSA	with	0.1%	Tween	20	 for	1	hour.	Primary	and	 secondary	antibodies	were	PDCD4	
(1:1000;	 #9535	D29C6;	 Cell	 Signaling	 Technology),	 GAPDH	 (1:2000;	 ab9485;	 Abcam),	
goat	anti-rabbit	 IgG-HRP	(1:10000;	sc-2004;	Santa	Cruz	Biotechnology)	and	goat	anti-
mouse	 IgG-HRP	 (1:10000;	 sc-2005;	 Santa	Cruz	Biotechnology)	 incubated	 in	0.1%	BSA	
with	0.1%	Tween-20	overnight.	Immunoblots	were	developed	using	WesternBright	ECL	
Spray	 (Advansta,	 K-12049-D50),	 images	were	 captured	 via	C-DiGit	 Chemiluminescent	
Western	 Blot	 Scanner	 and	 densitometry	 analysis	was	 conducted	 using	 Image	 Studio	
Version	5.2	Software.		
	
Immunohistochemical	staining	
Immunohistochemical	staining	of	peritoneal	membrane	study	samples	was	performed	
on	 5	 μm	 sections	 mounted	 on	 glass	 slides	 as	 previously	 described32.	 After	
deparaffinization	 and	 rehydration	 the	 sections	 were	 incubated	 in	 3%	 hydrogen	
peroxide.	Heat-induced	 antigen	 retrieval	was	 performed	 in	 a	microwave	oven,	 using	
0.005	M	citrate	buffer	(pH	6).	Polyclonal	rabbit	anti	p-SMAD2/3	(Santa	Cruz,	California,	
sc-11769)	 was	 incubated	 for	 1	 h	 at	 room	 temperature	 (1:100).	 Incubation	 with	
biotinylated	 secondary	 reagents	 (Vector)	 for	 30	 min	 was	 followed	 addition	 of	 ABC	
reagent	 (Vector)	 and	 detection	 using	 33Diaminobenzidine	 (DAB,	 Sigma,	
Taufkirchen,	Germany)	with	haematoloxylin	counterstain.	
	
Aperio	Analysis	
Immunohistochemical	 images	 were	 captured	 and	 evaluated	 using	 Aperio	 Precision	
Image	Analysis	Software	(USA).	The	Positive	Pixel	Count	Algorithm	(version	9)	output	
was	 used	 to	 calculate	 total	 p-SMAD2/3	 staining.	 Input	 algorithm	 parameters	 are	
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specific	color	ranges	in	the	HSI	colorspace	(Hue	value	0.1;	Hue	width	0.5)	and	intensity	
ranges	to	differentiate	between	weak,	medium,	strong	and	negative	staining.		Intensity	
thresholds	(upper/lower	limit):	weak	220/175,	medium	(175/100),	strong	(100/0)	and	
negative	 (255/220).	 Thresholds	 were	 optimized	 and	 validated	 specifically	 for	 p-
SMAD2/3.	 Positivity	 was	 calculated	 using	 numbers	 of	 negative	 pixels	 (Nn)	 and	 total	
pixels	(Ntotal)	using	the	formula:	(Ntotal-Nn)/(	Ntotal).	
	
Statistical	Analysis	
Differences	 between	 two	 individual	 experimental	 groups	 of	 normally	 distributed	
values	were	compared	by	two-tailed	t	test,	for	multiple	comparisons,	ANOVA	followed	
by	post	hoc	Holm-Sidak’s	test	was	used.	For	clinical	data,	Pearson’s	correlations	were	
used	for	normally	distributed	variables,	transformed	as	necessary,	and	Spearman’s	for	
other	 variables.	 Multivariable	 linear	 regression	 with	 backwards-stepwise	 variable	
selection	was	 performed	 for	 natural	 log	 transformed	miR-21	 variables,	 and	 to	 avoid	
problems	with	suppressor	effects,	dialysate	cytokine	values	were	entered	as	a	block.		
	
miRNA	 Array	 data	 were	 analyzed	 using	 GenePix	 Pro	 software,	 spot	 data	 were	
considered	valid	probe	hybridization	when	signal	intensity	was	greater	than	the	mean	
intensity	of	the	background	signal	plus	2	standard	deviations.	A	normalization	step	for	
each	specific	miRNA	adjusted	median	value	was	subsequently	performed.	The	relative	
miRNA	expression	 levels	were	determined	by	comparing	the	mean	signal	 intensity	of	
the	 real	hybridized	spots	with	 their	average	value	across	 the	microarray	experiment.	
To	reliably	compare	data	from	multiple	chips,	a	quantile-normalization	was	applied	to	
the	values.	These	microRNA	profiling	datasets	can	be	found	in	GEO	(GSE79006).	
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mRNA	array	data	processing	and	normalization	was	performed	using	 the	Babelomics	
software30,33.	 Fluorescence	 raw	 signal	 from	 each	 probe	 was	 corrected	 with	 the	
subtraction	of	local	background	and	normalized	with	the	loess	method	(within	arrays)	
or	the	quantile	method	(between	arrays).	Fold	change	for	a	gene	was	determined	as	a	
quotient	between	normalized	data	from	samples	under	study.	Statistics	for	differential	
expression	was	obtained	with	Limma	One	Class	or	Limma	Two	Class	test	and	corrected	
for	multiple-test	with	FDR	(False	Discovery	Rate;	Benjamini	&	Hochberg).	Genes	with	
fold	 change	 ≤0.5,	 and	 FDR≤0.01,	 were	 considered	 repressed.	 mRNA	 array	 changes	
displayed	here	 indicate	gene	 rather	 than	 transcript	 variant	 level.	mRNA	array	 results	
presented	in	this	article	can	be	found	in	GEO	(GSE92455)30.	
	
	
Results	
	
Mesothelial	miRNA	profile	is	altered	by	TGF-β1		
Before	profiling	overall	mesothelial	miRNA	expression	a	characterization	of	responses	
to	 TGF-β1	 was	 performed	 using	 primary	 cultures	 of	 mesothelial	 cells	 with	 replicate	
experiments	using	cells	from	different	omental	donors	(Supplemental	Figure	1	and	2).	
These	results	demonstrated	that	 in	primary	HPMCs	from	multiple	donors,	1	ng/ml	of	
TGF-β1	 induced	 changes	 consistent	with	 an	MMT	 process	 after	 48	 h.	 Global	miRNA	
expression	 was	 then	 quantified	 by	 hybridization	 array.	 Four	 independent	 biological	
replicates	from	different	donors	displayed	high	consistency	(Supplemental	Figure	3).	A	
total	 of	 699	miRNAs	 were	 detected	 in	 at	 least	 three	 samples	 and	 were	 included	 in	
subsequent	analysis.	95	of	699	miRNAs	were	differentially	regulated	by	TGF-β1.	MiR-
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21	 and	miR-31	 were	 highly	 expressed	 by	 HPMCs	 and	 induced	 by	 TGF-β1	 treatment	
(Figure	 1A).	 MiR-29b,	 previously	 shown	 to	 limit	 fibrosis	 when	 over-expressed	 in	 a	
mouse	 PD	 fluid	 infusion	 model2,	 was	 detected	 at	 high	 signal	 intensity,	 but	 no	
significant	 change	was	observed	 in	 response	 to	 TGF-β1	 (fold	 change:	 0.95x,	 p=0.61).	
Additional	miRNAs	previously	associated	with	peritoneal	membrane	transport	change	
and	 fibrosis	were	 detected	 at	 low	 signal	 intensity	 in	 this	 profile	 and	 did	 not	 change	
significantly	 in	 response	to	TGF-β1	 (including	miRs	 -15a,	 -17,	 -30,	 -192,	 -200c,	 -377,	 -
589).	
	
Up-regulation	 of	miR-21	 and	miR-31	 in	 primary	 HPMCs	was	 validated	 using	miRNA-
specific	 Taqman	 RT-qPCR	 assays	 (fold	 change:	miR-21,	 1.8x,	 p=0.012;	miR-31,	 1.7	 x,	
p=0.004	 (Figure	 1B	 and	 Supplemental	 Figure	 4A).	 Subsequently,	miR-21	 and	miR-31	
expression	was	evaluated	in	PDE-derived	HPMCs	cultured	ex	vivo,	divided	as	previously	
described4	into	those	exhibiting	phenotypic	changes	consistent	with	early	(E:	epithelial	
phenotype)	 or	 late	 (NE:	 non-epithelial	 phenotype)	 mesothelial	 to	 mesenchymal	
transition.	 MiR-21	 exhibited	 a	 stepwise	 increase	 in	 expression	 through	 cells	 of	
progressively	 more	 mesenchymal	 phenotype	 (Control,	 incubated	 with	 TGF-β1,	
effluent-derived	epithelioid,	effluent-derived	non-epithelioid)	(Figure	1C).	Elevation	of	
miR-31	in	this	model	was	also	confirmed	(Supplemental	Figure	4B).		
	
TGF-β1	 signaling	 is	 activated,	 and	 miR-21	 expression	 is	 increased,	 in	 PD	 patient	
peritoneal	membrane	biopsies		
TGF-β1	signaling,	miR-21	and	miR-31	expression	were	analyzed	in	the	mesothelial	and	
sub-mesothelial	cell	layers	of	patients	undergoing	PD.	In	order	to	evaluate	the	effects	
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of	the	therapy,	distinct	from	associated	vascular	pathology	or	other	comorbidity	that	
may	 be	 present	 in	 biopsies	 from	 adult	 patients,	 samples	 from	 the	 International	
Pediatric	 Membrane	 Biopsy	 Registry	 were	 studied.	 Children	 undergoing	 PD	 with	
conventional	 and	 with	 biocompatible	 fluids	 were	 examined,	 and	 compared	 with	
uremic	and	non-uremic	controls	(n=11	per	group,	mean	age	at	biopsy:	PD	conventional	
9.1	years,	PD	biocompatible	8.9	years,	control	uremic	9.6	years,	control	non-uremic	8.0	
years;	 mean	 duration	 of	 PD:	 PD	 conventional	 30	 months,	 PD	 biocompatible	 31	
months).	 α-SMA	 staining	 was	 used	 as	 an	 indictor	 of	 fibrogenesis	 in	 these	 samples	
(Supplemental	Figure	5)	while	SMAD2	and	SMAD3	phosphorylation	were	determined	
as	a	measure	of	TGF-β1	activity.	Phospho-SMAD2/3	staining	of	formalin-fixed	paraffin	
embedded	 (FFPE)	 samples	 was	 measured	 using	 Aperio	 Precision	 Image	 Analysis	
Software	and	a	count	algorithm	for	positive	pixel	detection	together	with	positive	and	
negative	controls	(Figure	2A-C).	The	mesothelial	and	sub-mesothelial	compact	zone	of	
PD	 patients	 displayed	 enhanced	 TGF-β1	 pathway	 activation	 compared	with	 controls	
(Figure	 2A-C).	 Enhanced	 p-SMAD2/3	 signal	 was	 observed	 in	 the	mesothelium	 of	 PD	
patients	 under	 conventional	 PD	 fluid	 treatment	 compared	with	 controls	 (Figure	 2C).	
MiRNA	analysis	of	manually	micro-dissected	FFPE	samples	also	showed	an	increase	in	
miR-21	 expression	 in	 the	 mesothelium	 of	 PD	 patients	 (Figure	 2D).	 Significant	 up-
regulation	 of	miR-21	was	 evident	 following	 PD	 treatment	when	 all	 the	 groups	were	
compared	with	controls	(Figure	2D).	Due	to	a	high	variability	between	samples	in	the	
control	 group,	 no	 difference	was	 seen	 between	 healthy	 controls	 and	 PD	 patients	 in	
miR-31	peritoneal	membrane	expression.	However,	a	trend	of	up-regulation	in	miR-31	
expression	 was	 observed	 between	 uraemic	 controls	 and	 PD	 patients	 (Supplemental	
Figure	4C).	
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Previous	studies	have	identified	direct	targeting	by	miR-21	of	programmed	cell	death	
protein	4	(PDCD4)34-36,	and	sequence	analysis	demonstrated	a	conserved	target	site	for	
miR-21	 (Supplemental	Figure	6F).	To	confirm	that	 this	was	 relevant	 in	 the	peritoneal	
membrane	 in	vivo,	expression	of	PDCD4	was	examined	in	samples	from	the	pediatric	
peritoneal	membrane	biopsy	registry.	Peritoneal	membrane	biopsies	from	PD	patients	
showed	a	significant	down-regulation	in	PDCD4	expression	in	the	mesothelial	and	sub-
mesothelial	 compact	 zones	 when	 compared	 with	 controls	 (Figure	 2E-G).	 Taken	
together,	 these	data	 are	 in	 line	with	 repression	of	 PDCD4	by	miR-21	 contributing	 to	
MMT	and	promotion	of	fibrosis	in	the	peritoneal	membrane.	
	
MiR-21	expression	in	PD	Effluent	correlates	with	clinically	important	parameters	
To	assess	 the	potential	of	miR-21	as	a	biomarker,	miRNA	expression	was	analyzed	 in	
patient	PDE	samples.	Initial	experiments	demonstrated	stability	of	miRNA	signal	for	at	
least	 8h	 following	 sample	 collection	 (data	 not	 shown).	 Subsequently,	 samples	 of	
effluent	 dialysate	 following	 a	 4-hour	 standardized	 dwell	 in	 a	 cohort	 of	 230	 patients	
recruited	 to	The	Global	Fluid	Study24	 in	a	 single	center	were	analyzed.	Supplemental	
Table	 1	 displays	 baseline	 clinical	 characteristics	 of	 the	 patients.	 When	 measured	 in	
effluent	of	prevalent	PD	patients,	miR-21	and	miR-31	expression	 levels	were	strongly	
increased	in	comparison	with	incident	cases	(fold	change:	miR-21	3.26x,	p=0.001;	miR-
31,	1.84	x,	p=0.0007)	(Figure	3A	and	Supplemental	Figure	7).	
	
To	 investigate	 the	 relationship	 between	 miR-21,	 miR-31	 and	 parameters	 associated	
with	poor	PD	outcome	we	performed	an	exploratory	correlation	analysis	in	which	miR-
21	 better	 correlated	 with	 parameters	 associated	 with	 an	 inflammatory	 condition	
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(Supplemental	Table	2).	In	order	to	understand	the	relevance	of	these	variables	for	the	
described	miR-21	 up-regulation	we	 performed	 a	multivariable	 linear	 regression	with	
backwards-stepwise	 variable	 selection	 for	 all	 parameters	 included	 in	 Supplemental	
Table	 2	 and	 miR-21	 or	 miR-31	 (Table	 2	 and	 Supplemental	 Table	 3).	 Consequently,	
stepwise	variable	selection	determined	a	group	of	 tighter	risk	 factors	that	associated	
with	 miR-21	 in	 predicting	 PD	 outcome.	 miR-21	 associated	 with	 dialysate	 Icodextrin	
usage	R=0.52,	 (95%	 confidence	 intervals	 0.20,	 0.84),	 peritonitis	 count	R=0.16,	 (0.03,	
0.29),	miR-31	R=0.52	(0.15,	0.90)	and	dialysate	cytokines	(Table	2).	miR-31	associated	
with	 biocompatible	 solution	 use	 R=0.18	 (-0.04,	 0.40),	 use	 of	 CAPD	 vs.	 APD	 R=0.14	
(0.02,	0.25),	miR-21	R=0.087	 (0.038,	0.136),	peritonitis	 count	R=0.052	 (0.006,	0.098),	
plasma	 albumin	 R=0.0096	 (-0.001,	 0.020)	 and	 urine	 volume	 R=-0.0001	 (-0.00017,	 -
0.00003	(Supplemental	Table	3).	Recent	work	shows	that	IL-6	and	IFN-γ	cooperate	to	
shift	 acute	 peritoneal	 inflammation	 into	 a	 more	 chronic	 pro-fibrotic	 state	 following	
recurrent	 inflammatory	 episodes37.	 IL-6	 concentration	 in	 PD	 effluent	 is	 the	 most	
significant	 known	 predictor	 of	 peritoneal	 small	 solute	 transport	 rate	 (PSTR)24.	While	
IFN-γ	 shows	 a	 strong	 correlation	 with	 localized	 intraperitoneal	 inflammatory	
networks24.	 In	 the	 current	 study,	 association	 between	 miR-21	 and	 IL-6	 was	 of	
borderline	significance	on	multivariable	 linear	regression	(R=0.28,	95%	CI	 -0.02,	0.58)	
while	 dialysate	 IFN-γ	 was	 highly	 significant	 (R=-0.77,	 95%	 CI	 -1.21,	 -0.33)	 when	
adjusted	 for	 dialysate	 IL-6.	 Here,	 we	 used	 values	 from	 the	 range	 of	 dialysate	 IFN-γ	
stratified	 by	 the	 25th,	 50th	 and	 75th	 centiles	 for	 dialysate	 IL-6	 and	 showed	 strong	
prediction	of	miR-21	expression	(Figure	3B).		
	
Identification	of	miR-21	targets	that	may	contribute	to	MMT	during	PD	therapy	
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PDCD4	 is	 an	 important	 effector	of	miR-21-induced	 fibrotic	 change	 in	other	 contexts,	
and	here	we	have	found	PDCD4	to	be	down	regulated	in	the	peritoneal	membrane	of	
patients	 treated	 with	 PD	 (Figure	 2E-G).	 However,	 microRNAs	 typically	 have	 several	
hundred	targets	and	may	be	predicted	to	control	changes	in	cell	phenotype	via	broad	
actions	across	many	targets.	To	have	a	more	complete	understanding	of	how	miR-21	
up-regulation	may	 lead	 to	MMT	 and	 fibrosis	 in	 the	 peritoneal	membrane,	 predicted	
miR-21	 targets	were	 evaluated	 in	 an	 Affymetrix	 array	 dataset	 comprising	 profiles	 of	
control,	early-	and	late-MMT,	using	patient-derived	effluent	mesothelial	cells	cultured	
ex	vivo	as	previously	described4.	Overall,	774	genes	were	identified	as	down	regulated	
in	the	MMT	process,	including	274	transcripts	identified	as	down-regulated	specifically	
in	early	MMT	and	298	transcripts	in	late	MMT	(Figure	4A).	Independent	miR-21	target	
prediction	was	 undertaken	 using	 four	 different	 algorithms,	 and	 results	 subsequently	
combined,	comprising	Diana38,	39,	miRDB40,	41,	miRanda42,	43	and	TargetScan44,	45	(Figure	
4B).	 Single	 miR-21	 algorithm	 predictions	 were	 inter-crossed	 to	 identify	 targets	 that	
were	 predicted	 by	 three	 or	 more	 algorithms	 (Figure	 4B).	 These	 predicted	 miR-21	
targets	were	further	inter-crossed	with	the	genes	identified	as	down	regulated	in	MMT	
(Figure	 4C).	 Five	 miR-21	 predicted	 targets	 were	 identified	 to	 be	 differentially	 down	
regulated	 during	 early-MMT,	 two	 in	 the	 late-MMT	 course	 and	 ten	when	 the	whole-
MMT	 was	 evaluated	 (Figure	 4C).	 These	 included	 -early	 MMT-	 Natriuretic	 Peptide	 B	
(NPPB),	PDZD2,	 S100	 calcium-binding	 protein	 A10	 (S100A10),	 SAM	And	 SH3	Domain	
Containing	 1	 (SASH1)	 and	Metalloproteinase	 inhibitor	 3	 (TIMP3);	 -late	MMT-	PDZD2	
and	SASH1;	and	 	-whole	MMT-	Absent	 In	Melanoma	1-Like	(AIM1L),	CASK	Interacting	
Protein	1	(CASKIN1),	Dual	Specificity	Phosphatase	8	(DUSP8),	Fibroblast	Growth	Factor	
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18	 (FGF-18),	Matrilin	 2	 (MATN2),	 Neural	 EGFL	 Like	 2	 (NELL2),	PDZD2,	 (Ras	 Homolog	
Family	Member	B	(RHOB),	SASH1	and	Sprouty	RTK	Signaling	Antagonist	1	(SPRY1).		
	
Evaluation	of	miR-21	targets	in	HPMCs	under	MMT	conditions	
The	above	analysis	provided	14	predicted	miR-21	targets	identified	as	down	regulated	
in	 ex-vivo	 cultured	 mesothelial	 cells	 exhibiting	 MMT.	 These	 14	 genes	 were	
subsequently	examined	by	RTqPCR	 in	mesothelial	 cells	 exhibiting	progressively	more	
mesenchymal	phenotype	(control,	incubated	with	TGF-β1,	effluent-derived	epithelioid,	
effluent-derived	non-epithelioid).	11	of	14	genes	demonstrated	a	pattern	of	expression	
consistent	with	miR-21	regulation	in	this	model	(Figure	5	and	Supplemental	Figure	8).		
mirVana	miR-21	mimic	and	inhibitor	delivery	in	HPMCs	was	used	to	evaluate	these	11	
predicted	 targets.	 Five	 targets	 showed	 significant	 down	 regulation	 by	miR-21	mimic	
and	up	 regulation	by	 inhibitor,	namely	PDZD2,	S100A10,	FGF-18,	MATN2	 and	PDCD4	
(Figure	6).	CASKIN1,	NELL2	and	DUSP8	were	up	regulated	by	miR-21	inhibitor	but	did	
not	show	significant	change	in	response	to	enforced	expression	of	miR-21,	and	SASH1	
and	AIM1L	expression	was	not	affected	by	enforced	expression/repression	of	miR-21	
(Supplemental	Figure	9).	
	
Analysis	of	3’UTR	target	site	types	and	conservation	for	the	identified	targets	PDZD2,	
S100A10,	 FGF-18,	 MATN2	 and	 miR-21	 across	 different	 animal	 species	 is	 shown	 in	
Supplemental	Figure	6.	PDZD2	3’UTR	was	found	to	contain	two	different	seed	region	
consensus	sites,	while	the	remainder	of	the	targets	identified	each	had	a	single	miR-21	
predicted	binding	site	in	the	UTR	(Supplemental	Figure	9).	Sites	identified	were	highly	
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conserved	 and	 energetically	 favorable	 (8mer	 or	 7mer-m8	 sites,	 46)	 in	 keeping	 with	
direct	regulation	of	these	targets.		
	
	
Discussion	
	
PD	 is	 an	 effective	 form	 of	 renal	 replacement	 therapy,	 but	 is	 often	 limited	 by	
deterioration	 in	 the	 structural	 and	 functional	 characteristics	 of	 the	 peritoneal	
membrane.	New	biomarkers	are	needed,	to	help	individualize	therapy	in	PD,	to	serve	
as	appropriate	surrogates	in	clinical	trials,	and	to	guide	development	of	innovations	in	
the	therapy.	miRNAs	show	promise	as	biomarkers	 in	patients	with	kidney	disease6,	 47	
but	 there	has	been	 limited	 study	 to	date	 in	PD	patients.	Our	data	 show	 that	miR-21	
expression	 is	 increased	 in	 several	well-established	models	 associated	with	 structural	
and	 functional	 alterations	 of	 the	 peritoneal	 membrane	 during	 peritoneal	 dialysis.	
Moreover,	we	showed	that	miRNAs	can	be	measured	in	the	peritoneal	dialysis	effluent	
from	 PD	 patients,	 where	 miR-21	 correlates	 with	 clinical	 parameters	 indicating	 poor	
outcome	on	PD.			
	
The	 peritoneal	 membrane	 has	 a	 complex	 structure,	 and	 includes	 cells	 of	 multiple	
lineages.	 The	 mesothelial	 cell	 layer	 forms	 the	 interface	 between	 dialysate	 and	
membrane,	 and	 plays	 an	 important	 role	 in	 determining	 changes	 associated	with	 PD	
therapy	 failure9.	 TGF-β1	 plays	 a	 pivotal	 role	 in	 PD	 treatment-driven	 membrane	
alterations3	 and	 here	 we	 have	 defined	 a	 pattern	 of	 microRNA	 changes	 occurring	 in	
primary	human	mesothelial	cells	in	response	to	TGF-β1.	These	data	showed	abundant	
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expression	of	miR-21	 in	mesothelial	 cells,	 and	 increased	 expression	when	 cells	were	
incubated	 with	 TGF-β1.	 Previous	 studies	 have	 characterized	 the	 phenotype	 of	
mesothelial	cells	isolated	from	PDE	from	patients	and	demonstrated	that	a	progressive	
loss	 of	 epithelial	 morphology	 is	 accompanied	 by	 a	 decrease	 of	 Cytokeratins	 and	 E-
cadherin	 expression	 as	 well	 as	 an	 induction	 of	 the	 transcriptional	 repressor	 Snail4.	
Further	 experiments	 found	 increased	 miR-21	 in	 PDE-derived	 mesothelial	 cells	 with	
these	mesenchymal	 characteristics,	 linking	miR-21	 to	mesothelial	 cell	 characteristics	
previously	shown	to	define	an	adverse	response	to	PD4.	
	
Subsequently,	 miR-21	 expression	 was	 examined	 in	 peritoneal	 membrane	 biopsies.	
Fibro-proliferative	 changes	 have	 been	 delineated	 in	 the	 peritoneal	membrane	 of	 PD	
patients,	 together	 with	 more	 minor	 changes	 in	 uremic	 (pre-dialysis)	 patients48.	
Peritoneal	 vascular	 changes	are	also	 frequently	evident	 in	adult	patients,	which	may	
make	 it	 difficult	 to	 separate	 therapy-induced	 alterations	 from	 those	 related	 to	 the	
propensity	of	individuals	with	CKD	to	accelerated	cardiovascular	disease.	At	the	time	of	
PD	 onset,	 the	 pediatric	 peritoneal	 tissue	 is	 devoid	 of	 vascular	 alterations	 and	 tissue	
aging.	 In	 order	 to	 determine	 the	 “pure”	 effects	 of	 the	 therapy,	 pediatric	 biopsy	
samples	were	 examined,	 from	 the	 International	 Pediatric	 Peritoneal	 Biopsy	 Registry.	
TGF-β1	 signaling	 was	 clearly	 evident	 in	 biopsies	 from	 PD	 patients	 compared	 to	
controls,	 and	 was	 associated	 with	 increased	 miR-21	 and	 decreased	 PDCD4	 in	 the	
mesothelial	and	sub-mesothelial	zones.	Given	recent	fate	mapping	studies,	which	have	
delineated	 an	 important	 contribution	 of	 sub-mesothelial	 fibroblasts	 to	 peritoneal	
fibrosis	in	mouse	models5,	understanding	the	potential	role	of	miRNAs	including	miR-
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21	 in	 sub-mesothelial	 fibroblast	 phenotype	may	also	be	 an	 important	 future	 area	of	
study.	
	
Inflammatory	markers,	most	notably	Il-6,	may	be	measured	in	the	dialysis	effluent	as	
an	 indirect	measure	 of	 intraperitoneal	 inflammation49,	 although	 a	 biomarker	 for	 the	
extent	 of	 peritoneal	 fibrosis	 is	 still	 lacking.	 Multivariable	 linear	 regression	 with	
backwards-stepwise	 variable	 selection	was	performed,	 to	understand	associations	of	
miR-21	 expression	 with	 clinical	 characteristics	 and	 measures	 of	 intraperitoneal	
inflammation.	 Of	 note,	 miR-21	 correlated	 with	 Icodextrin	 usage,	 which	 has	 been	
previously	 associated	 with	 multiple	 indicators	 of	 local	 inflammation24,	 50.	 The	
relationship	between	 intra-peritoneal	 inflammation	and	membrane	 function	has	also	
been	recently	investigated	in	PD	patients24,	51.	In	the	current	study,	we	also	found	miR-
21	 association	 with	 peritonitis	 count	 and	 dialysate	 IFN-γ,	 IL-6,	 TNF-α	 and	 IL-1β,	
suggesting	a	primary	response	to	local	factors	and	inflammatory	stimuli.	IFN-γ52,	TNF-α	
and	 IL-1β53	 induce	 IL-6	 secretion	 by	 mesothelial	 cells,	 the	 major	 producers	 of	 IL-6	
within	the	peritoneal	cavity53,	54.	IL-6,	in	turn,	is	also	an	important	inducer	of	miR-21	in	
multiple	 myeloma,	 mammary	 epithelium,	 hepatocellular	 carcinoma	 (HCC),	 oral	
squamous	 cell	 carcinoma	 and	 keratinocytes	 via	 STAT	 signaling55-59,	 providing	 a	
potential	 mechanistic	 basis	 for	 the	 association	 of	 pro-inflammatory	 cytokines	 with	
miR-21	expression	in	the	context	of	peritoneal	dialysis.		
	
Here,	we	identified	miR-21	mediated	repression	of	PDCD4	in	mesothelial	cells.	PDCD4	
down-regulation	triggers	an	increase	in	SNAIL	protein	and	a	consequent	decrease	in	E-
cadherin	expression,	which	in	turn	stimulates	β-catenin/TCF	dependent	transcription34-
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36.	Thus,	miR-21	down-regulation	of	PDCD4	in	HPMCs	may	not	only	contribute	to	the	
detachment	 of	 inter-mesothelial	 adhesions	 but	 also	 to	 the	 acquisition	 of	 a	 new	
molecular	program,	dictating	a	distinct	expression	regulation	characteristic	of	an	MMT	
process.	 In	addition,	we	identified	four	new	miR-21	targets	that	may	be	 important	 in	
the	 context	 of	 PD	 therapy	 associated	 fibrogenesis,	 PDZD2,	 S100A10,	 FGF-18	 and	
MATN2.	Previous	 literature	has	 linked	a	 reduction	of	expression	of	 these	genes	with	
fibrosis	 in	different	contexts.	 In	brief,	mice	with	conditional	deletion	of	FGF-18	in	the	
lung	 displayed	 thicker	 interstitial	mesenchymal	 compartments,	 embedded	 capillaries	
and	 reduced	 cell	 proliferation60	 while	 FGF-18	 over-expression	 in	 lung	 decreased	
extracellular	matrix	and	connective	tissue	components	including	matrilin-261.	Between	
the	 multiple	 functions	 attributed	 to	 S100A10	 probably	 the	 most	 physiologically	
remarkable	 is	 its	 extracellular	 function	 as	 a	 plasminogen	 receptor,	 mediating	 its	
activation	 by	 plasminogen	 activators,	 stimulating	 plasminogen	 conversion	 to	 wide	
protease	 plasmin	 and	 promoting	 fibrinolysis62.	 Indeed,	 S100A10-null	 mice,	 although	
viable,	showed	impaired	fibrinolysis	and	increased	tissue	fibrin	deposition	including	in	
lungs,	 liver,	 spleen	 and	 kidney	 compared	 to	wild-type	mice	 litter	mates62.	Matrilin-2	
binds	 collagen	 I	 and	 non-collagenous	 proteins63	 contributing	 to	 extracellular	 matrix	
supra-molecular	 organization.	Matrilin-2	 knock-down	 induced	 serious	 defects	 in	 skin	
wound	healing64.	Additionally,	Ichikawa	et	al.	2008	showed	that	matrilin-2	reduction	in	
human	 keratinocyte	 cells	 induced	 cell	 migration	 into	 a	 wound64.	 In	 vitro	 treatment	
with	 recombinant	 sPDZD2	 induces	p53	up-regulation	 in	human	prostate	 cancer	 (DU-
145),	breast	adenocarcinoma	(MCF-7)	and	 liver	cancer	(Hep-G2)	cell	 lines65,	and	such	
altered	p53	activity	may	inhibit	EMT66.	Importantly	though,	PDZD2	is	expressed	in	the	
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nucleus	and	also	secreted	following	cleavage67	suggesting	a	potentially	complex	role	in	
these	processes.		
	
In	 PD	 patients,	 continuous	 dialysis	 fluid	 exchanges	 allow	 easy	 access	 to	 monitor	
peritoneal	miRNA	expression.	Previous	studies	have	demonstrated	that	Il-6	and	IFN-γ	
are	strong	predictors	of	MC	damage	in	PD	patients,	and	are	mechanistically	 linked	to	
peritoneal	fibrosis	following	infection37.	Nevertheless,	no	biomarker	or	combination	of	
biomarkers	 yet	 allows	 prediction	 of	 outcome	 for	 the	 single	 patient	 or	 individualized	
therapy.	In	this	study,	microRNAs	were	found	to	be	stable	and	readily	detected	in	the	
peritoneal	dialysis	effluent,	emphasizing	their	potential	as	a	class	of	biomarker	in	this	
context.	MiR-21	was	 found	to	be	up	regulated	 in	mesothelial	 cells	undergoing	MMT,	
and	 in	 peritoneal	 membrane	 undergoing	 fibrosis	 in	 the	 context	 of	 PD.	 miR-21	 was	
further	found	to	be	stable	in	dialysis	effluent,	and	PD	effluent	levels	to	correlate	with	
different	 clinically	 important	 parameters	 themselves	 linked	 to	membrane	 change	 in	
this	patient	group.	These	data	identify	miR-21	as	a	promising	biomarker	to	monitor	the	
peritoneal	membrane	of	patients	undergoing	PD	therapy.	
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Figure	Legends	
Figure	 1.	 miRNA	 profiling	 in	 TGF-β1-stimulated	 HPMCs	 and	 miRNA	 changes	
confirmation	 in	 in	 vitro	 and	 ex	 vivo	models.	 (A)	 Three-dimensional	 scatter	 plot	 of	
miRNA	 expression	 following	 1ng/ml	 of	 TGF-β1-treatment	 for	 48	 h	 (x	 axis:	 log2	 fold	
change	of	the	normalized	miRNA	signal	(mean	of	at	least	three	replicates);	y	axis:	-log10	
p	value	obtained	from	one-way	analysis	of	the	variance	(ANOVA)	followed	by	Fisher’s	
least	significant	difference	(LSD)	post	hoc	analysis;	z	axis:	log10	of	the	level	of	baseline	
expression	in	mesothelial	cells).	(B)	miR-21	expression	validation.	Control	-	white	bars,	
TGF-β1	 (1ng/ml,	 48	 h)	 –	 black	 bars.	 (C)	 Relative	 expression	 of	 miR-21	 in	 control	
omentum-derived	 mesothelial	 cells	 (HPMCs),	 TGF-β1	 treated	 (1ng/ml,	 48h)	 and	
cultured	 peritoneal	 effluent	 derived	 (PDE)	 cells	with	 epithelial	 (E)	 and	 non-epithelial	
(NE)	 phenotype.	 Expression	 of	 miR-21	 was	 analyzed	 by	 RT-qPCR	 and	 normalized	 to	
miR-191	expression.	Data	were	analyzed	by	paired	t	test	or	one-	way	ANOVA	followed	
by	 post-hoc	 Holm-Sidak’s	 test	 comparing	 each	 condition	 mean	 with	 the	 control	
omentum-derived	mean.	Data	represent	the	mean	S.E.M.	from	five	independent	donor	
experiments.	*p	˂	0.05.	
Figure	2.	miR-21	expression		is	up-regulated	at	the	peritoneal	membrane	in	peritoneal	
dialysis	patients.	Formalin-fixed	paraffin	embedded	(FFPE)	samples	were	stained	for	p-
SMAD2/3	 (A-C)	and	PDCD4	 (E-G),	 and	manually	macro-dissected	 to	measure	 relative	
expression	 of	miR-21	 (D)	 from	 a	 total	 of	 44	 patients.	 (A)	Histological	 image	 analysis	
using	 Aperio	 Precision	 Image	 Analysis	 Software.	 Mesothelial	 and	 submesothelial	
compact	zone	selection	(upper	panel)	and	p-SMAD2/3	detection	of	the	area	of	interest	
by	the	Aperio	positive	pixel	count	algorithm	(lower	panel).	Negative	background	(blue),	
positive	 p-SMAD2/3	 detection	 (yellow-orange).	 Scale	 bar,	 300	 μm.	 	 (B)	 Higher	
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magnification	 image	 to	 demonstrate	 nuclear	 immunostaining	 of	 p-SMAD2/3	 and	
negative	control.	Scale	bar,	50	μm.	(C)	P-SMAD2/3	up-regulation.	Level	of	p-SMAD2/3	
staining	was	defined	using	a	 count	algorithm	 for	positive	pixel	detection.	 (D)	miR-21	
expression.	miR-21	 expression	was	 analysed	 by	 RT-qPCR	 and	 normalized	 to	miR-191	
expression.	 (E-G)	 Formalin-fixed	 paraffin	 embedded	 (FFPE)	 samples	 were	 PDCD4	
stained.	(E)	Histological	image	analysis	using	Aperio	Precision	Image	Analysis	Software.	
Mesothelial	 and	 submesothelial	 compact	 zone	 was	 selected	 as	 area	 of	 interest	 and	
PDCD4	staining	was	quantified	by	the	aperio	positive	pixel	count	algorithm.	(F)	PDCD4	
negative	control.	 (G)	Positive	PDCD4	detection	(brown).	Scale	bar,	80	μm.	Data	were	
analyzed	 by	 one-way	 ANOVA	 followed	 by	 post-hoc	 Holm-Sidak’s	 test	 comparing	 all	
condition	means.	Data	represent	the	mean	S.E.M.	 from	eleven	age-matched	samples	
and	equal	average	PD	duration	between	PD	groups	 (n=44).	*p	˂	0.05;	***p	˂	0.005;	
****p	˂	0.001;	*****p	˂	0.0005.		
Figure	 3.	miR-21	 expression	 in	 peritoneal	 dialysis	 effluent	 (PDE)	 from	 PD	 patients	
(n=230).	 RNA	 from	230	 PDE	 samples	was	 isolated	 and	 relative	 expression	 of	miR-21	
was	 normalized	 to	 miR-191	 expression.	 (A)	 Up-regulation	 of	 miR-21	 expression	 in	
peritoneal	dialysis	effluent	 (PDE)	 from	prevalent	PD	patients	compared	with	 incident	
cases.	Data	were	analyzed	by	unpaired,	Mann-Whitney	test.	Data	represent	the	mean		
S.E.M.	 from	samples.	***p	˂	0.005.	 (B)	 Effect	of	 IL-6	and	 IFN-γ	on	miR-21	prediction	
levels.	The	predicted	variable,	miR-21,	was	log	transformed.	(n=230).		
Figure	4.	Mesothelial	to	mesenchymal	mRNA	array	changes	associated	to	PD	therapy	
in	 HPMCs	 and	 In	 silico	 target	 prediction	 to	 identify	 new	 miR-21	 targets	 that	 may	
contribute	 to	 the	 process.	 (A)	 Diagram	 displaying	 mRNA	 array	 changes	 comparing	
control	omentum	HPMCs	and	PDE	derived	MCs	with	epithelial	phenotype	(early-MMT,	
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green),	PDE	derived	MCs	with	epithelial	phenotype	and	non-epithelial	phenotype	(late-
MMT,	yellow),	and	control	omentum	HPMCs	and	PDE	derived	MCs	with	non-epithelial	
phenotype	(whole-MMT,	red).	(B)	miR-21	target	prediction	using	Diana	(blue),	miRDB	
(brown),	miRanda	 (green)	 and	 TargetScan	 (red)	 inter-crossed	 using	Venn	diagram	 to	
identify	 targets	 that	 were	 predicted	 by	 three	 or	 more	 algorithms.	 (C)	 Diagram	
displaying	 miR-21	 targets	 predicted	 and	 identified	 in	 (B)	 further	 inter-crossed	 using	
Venn	 diagram	 with	 the	 mRNA	 array	 changes	 identified	 in	 (A;	 green,	 yellow,	 red).	
Common	 targets	 identified	 by	 (A)	 and	 (B)	 inter-crossed	 lists	 are	 shown	 into	 squares	
with	 the	 respective	 MMT	 color	 (top	 left,	 early-MMT;	 top	 right,	 late-MMT;	 bottom,	
whole-MMT).	
Figure	 5.	 Predicted	 miR-21	 target	 profiling	 in	 a	 model	 of	 progressive	 peritoneal	
membrane	deterioration.	(A-N)	Relative	mRNA	expression	in	control	omentum-derived	
mesothelial	 cells	 (HPMCs),	 TGF-β1	 treated	 (1ng/ml,	 48h)	 and	 cultured	 peritoneal	
effluent	derived	(PDE)	cells	with	epithelial	(E)	and	non-epithelial	(NE)	phenotype	(n=5	
for	each	group).	 (A)	NPPB.	 (B)	PDZD2.	 (C)	S100A10.	 (D)	SASH1.	 (E)	TIMP3.	 (F)	AIM1L.	
(G)	CASKIN1.	 (H)	DUSP8.	 (I)	 FGF18.	 (J)	MATN2.	 (K)	NELL2.	 (L)	RHOB.	 (M)	 SPRY1.	 (N)	
PDCD4	 (A-N)	 Target	 gene	 expression	 was	 analyzed	 by	 RT-qPCR	 	 and	 normalized	 to	
GAPDH.	 Data	 were	 analyzed	 by	 no	 matched	 one-way	 ANOVA	 followed	 by	 post-hoc	
Holm-Sidak’s	 test.	 Data	 represent	 the	 mean	 	 S.E.M.	 from	 five	 independent	 donor	
experiments.	*p	˂	0.05;	**p	˂	0.01;	***p	˂	0.005;	****p	<	0.001.		
Figure	 6.	miR-21	 target	 mRNA	 expression	 48h	 after	 miRNA	mimic	 (A,	 C,	 E,	 G,	 I)	 or	
inhibitor	(B,	D,	F,	H,	J)	delivery	in	HPMCs	at	concentrations	5-20pM	as	indicated.	miR-
control	(mimic	or	inhibitor)	–	white	bars,	miR-21	mimic	–	black	bars,	miR-21	inhibitor	–	
grey	 bars.	 (A,	 B)	 PDZD2.	 (C,	 D)	 S100A10.	 (E,	 F)	 FGF18.	 (G,	 H)	MATN2.	 (I,	 J)	 PDCD4.		
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Target	 gene	 expression	 was	 analyzed	 by	 RT-qPCR	 and	 normalized	 to	 GAPDH	
expression.	Data	were	analyzed	by	matched	factor	two-way	ANOVA	followed	by	post-
hoc	Holm-Sidak’s	test.	Data	represent	the	mean		S.E.M.	from	three	(miRNA	mimic)	and	
six	 (miRNA	 inhibitor)	 independent	donor	experiments.	*p	˂	0.05;	**p	˂	0.01;	***p	˂	
0.005;	****p	<	0.001.		
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Main	Tables	
Symbol	 Reverse	and	Forward	Primers	(5’-3’)	
E-Cadherin	
F:	5 	TCCCAATACATCTCCCTTCACA	3 	
R:	5 	ACCCACCTCTAAGGCCATCTTT	3 	
ZO-1	
F:	5 	GGAGAGGTGTTCCGTGTTGT	3 	
R:	5 	GGCTAGCTGCTCAGCTCTGT	3 	
Occludin	
F:	5 	TAAATCCACGCCGGTTCCTGAAGT	3 	
R:	5 	AGGTGTCTCAAAGTTACCACCGCT	3 	
Claudin-1	
F:	5 	CGGGTTGCTTGCAATGTGC	3 	
R:	5 	CCGGCGACAACATCGTGAC	3 	
Fibronectin	
F:	5 	CCGAGGTTTTAACTGCGAGA	3 	
R:	5 	TCACCCACTCGGTAAGTGTTC	3 	
Collagen1a1	
F:	5 	CATGTTCAGCTTTGTGGACCTC	3 	
R:	5 	TTGGTGGGATGTCTTCGTCT	3 	
Snail	
F:	5 	TTTACCTTCCAGCAGCCCTA	3 	
R:	5 	GGACAGAGTCCCAGATGAGC	3 	
α-SMA	
F:	5 	AACTGGGACGACATGGAAA	3 	
R:	5 	AGGGTGGGATGCTCTTCAG	3 	
GAPDH	
F:	5 	CCTCTGACTTCAACAGCGACAC	3 	
R:	5 	TGTCATACCAGGAAATGAGCTTGA	3 	
PDCD4	
F:	5 	TGGATTAACTGTGCCAACCA	3 	
R:	5 	TCTCAAATGCCCTTTCATCC	3 	
SPRY1	
F:	5 	AGATGCATGCCAGGTTTCCA	3 	
R:	5 	TAACGAACTGCCACTGCCAT	3 	
PTEN	
F:	5 	CGGCAGCATCAAATGTTTCAG	3 	
R:	5 	AACTGGCAGGTAGAAGGCAACTC	3 	
LATS2	
F:	5 	CAGATTCAGACCTCTCCCGT	3 	
R:	5 	CTTAAAGGCGTATGGCGAGT	3 	
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STK40	
F:	5 	CCAGTGCCCTTGCCTCATAA	3 	
R:	5 	AATCTCGGCTCAAAAGGGCA	3 	
	
Table	1:	RT-qPCR	Primer	Sequences.	Primer	sequences	designed	and	used	for	RT-qPCR	in	this	
study.	
Variable	 Coefficient	(95%	Confidence	Interval)	 p	value	
Icodextrin	Usage	 0.52	(0.20,	0.84)	 0.002	
Peritonitis	Count	 0.16	(0.03,	0.29)	 0.015	
Dialysate	IL-6	 0.28	(-0.02,	0.58)	 0.065	
Dialysate	TNF-α	 0.86	(-0.61,	2.34)	 0.25	
Dialysate	IFN-γ	 -0.77	(-1.21,	-0.33)	 0.001	
Dialysate	IL-1β	 0.69	(-0.89,	2.27)	 0.39	
Body	Mass	Index	 0.027	(-0.0004,	0.054)	 0.053	
	
Table	 2:	Multivariable	 Regression	 of	miR-21.	Multivariable	 linear	 regression	with	 backwards	
stepwise	variable	selection	for	parameters	listed	in	Supplemental	Table	2.	
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Supplemental	Figure	Legends	
Supplemental	 Figure	 1.	 TGF-β1	 represses	 epithelial	 and	 induces	mesenchymal	markers	in	mesothelial	cells.	Omentum-derived	mesothelial	cells	were	treated	with	TGF-β1	 at	 the	 concentrations	 shown.	 Epithelial	 markers:	 E-Cadherin,	 ZO-1,	Occludin	and	Claudin-1;	Mesenchymal	markers:	Fibronectin,	Collagen	I,	Snail	and	α-SMA.	 (A-B)	 TGF-β1	 concentration	 course.	 (A)	 Mesothelial	 markers.	 (B)	Mesenchymal	markers.	 Expression	 of	 all	markers	was	 analyzed	 by	RT-qPCR	 and	normalized	 to	 GAPDH	 expression.	 Data	 were	 analyzed	 by	 one-way	 ANOVA	followed	 by	 post-hoc	 Holm-Sidak’s	 test	 between	 treatments	 at	 each	 time	 point.	Data	represent	 the	mean	S.E.M.	 from	three	 independent	donor	experiments.	 *p	˂	0.05;	 **p	 ˂	 0.01;	 ***p	 ˂	 0.005.	 (C)	 Phenotypic	 time-course	 changes	 of	HPMCs	 in	culture	after	TGF-β1	 treatment.	Omentum-derived	mesothelial	 cells	were	 treated	for	0,	24,	48	and	72	h	with	TGF-β1	(1	ng/ml).	(0	and	24	h)	Characteristic	epithelial	morphology	of	polygonal	 shape	 cells	 from	a	 confluent	monolayer.	 (48	h)	Loss	of	epithelial	 morphology	 and	 acquisition	 of	 fibroblast-like	 form.	 (72	 h)	 Loss	 of	epithelial	morphology	and	acquisition	of	fibroblast-like	phenotype	with	disruption	of	 intercellular	 junctions	 characteristic	 of	 a	 migratory	 phenotype.	 One	representative	 experiment	 of	 three	 is	 shown.	 Zeiss	 Axiovert	 135	 microscope.	Magnification:	200x.			
Supplemental	 Figure	 2.	 TGF-β1	 represses	 epithelial	 and	 induces	mesenchymal	markers	 in	 mesothelial	 cells	 in	 a	 time	 dependent	 manner.	 Omentum-derived	mesothelial	 cells	were	 treated	with	TGF-β1	 for	 the	 time	points	 shown.	Epithelial	markers:	 E-Cadherin,	 ZO-1,	 Occludin	 and	 Claudin-1;	 Mesenchymal	 markers:	Fibronectin,	Collagen	I,	Snail	and	α-SMA.	(A-H)	TGF-β1	time	course.	Control	-	white	
bars,	TGF-β1	(1ng/ml)	-	black	bars.	 (A)	E-Cadherin.	(B)	ZO-1.	(C)	Occludin	1.	(D)	Claudin-1.	(E)	Fibronectin.	(F)	Collagen	 I.	(G)	 Snail.	(H)	α-SMA.	Expression	of	all	markers	 was	 analyzed	 by	 RT-qPCR	 and	 normalized	 to	 GAPDH	 expression.	 Data	were	 analyzed	 by	 one-	 and	 two-way	 ANOVA	 followed	 by	 post-hoc	 Holm-Sidak’s	test	between	treatments	at	each	time	point.	Data	represent	the	mean		S.E.M.	from	three	independent	donor	experiments.	*p	˂	0.05;	**p	˂	0.01;	***p	˂	0.005;	****p	˂	0.001.		TGF-β1	 down-regulated	 expression	 of	 epithelial	 markers	 E-cadherin,	 ZO-1,	Occludin	and	Claudin-1	at	48	h	(Figure	S1A).	This	effect	was	TGF-β1-concentration	dependent	 and	 showed	 a	 threshold	 for	 statistical	 significance	 at	 1	 ng/ml	 for	 E-cadherin	and	Occludin	(Figure	S1A).	 In	addition,	TGF-β1	up-regulated	expression	of	mesenchymal	markers	Fibronectin,	Collagen	 I,	 and	α-SMA	at	48	h	 (Figure	S1B	and	 S2	 E-H).	 Snail	 expression	 did	 not	 vary	 in	 mesothelial	 cells	 incubated	 with	different	 doses	 of	 TGF-β1	 after	 48	 h	 of	 treatment	 (Figure	 S1B).	 Time-course	experiments	 were	 then	 carried	 out	 to	 investigate	 temporal	 variation	 in	 TGF-β1	gene	 regulation.	 Down-regulation	 of	 epithelial	markers	was	 observed	 from	 48	 h	onwards	 (Figure	 S1A	 and	 S2	 A-D).	 The	 expression	 of	 epithelial	 markers	 ZO-1,	Claudin	and	Occludin	was	affected	by	cell	confluence	and	was	most	evident	after	72	 h	 of	 treatment	 (Figure	 S2	 B-D).	 By	 contrast,	 mesenchymal	 markers	 were	induced	by	24	h,	with	Snail	 expression	peaking	at	2	h	 (Figure	S2	E-H).	 Snail	has	been	described	 to	 be	 involved	 in	 the	 alterations	 of	 intercellular	 adhesion	during	the	MMT	process,	and	its	early	activity	here	may	contribute	to	the	 latter	changes	observed	 in	 epithelial	 markers	 (Figure	 S1A).	 Fibroblast-like	 architecture	 was	visible	 after	48	h,	 and	 these	 changes	were	most	 evident	 after	72	h	 (Figure	 S2C).	Phenotypic	 changes	 were	 not	 seen	 before	 24	 h	 (data	 not	 shown).	 In	 summary,	
these	results	demonstrated	that	in	primary	HPMCs	from	multiple	donors,	1	ng/ml	of	TGF-β1	induced	changes	consistent	with	an	MMT	process	after	48	h.	
Supplemental	 Figure	 3.	 miRNA	 profiling	 in	 TGF-β1-stimulated	 HPMCs.	Scatterplot	of	2	technical	replicates	showing	a	significant	correlation	for	all	miRNA	probes.		
Supplemental	 Figure	 4.	 miRNA	 profiling	 in	 TGF-β1-stimulated	 HPMCs	 and	miRNA	changes	confirmation	in	in	vitro	and	ex	vivo	models..	(A)	miR-31	expression	validation.	Control	-	white	bars,	TGF-β1	(1ng/ml,	48	h)	–	black	bars.	(B)	Relative	expression	of	miR-31	in	control	omentum-derived	mesothelial	cells	(HPMCs),	TGF-β1	treated	(1ng/ml,	48h)	and	cultured	peritoneal	effluent	derived	(PDE)	cells	with	epithelial	(E)	and	non-epithelial	(NE)	phenotype.	Data	represent	the	mean		S.E.M.	from	five	 independent	donor	experiments.	(C)	Formalin-fixed	paraffin	embedded	(FFPE)	samples	were	manually	macro-dissected	to	measure	relative	expression	of	miR-31	 from	 a	 total	 of	 44	 patients.	 miR-31	 expression	 	 is	 upregulated	 at	 the	peritoneal	 membrane	 in	 peritoneal	 dialysis	 patients	 compared	 with	 uremic	controls	 and	 is	 ns.	 Expression	 of	 miR-31	 was	 analyzed	 by	 RT-qPCR	 	 and	normalized	to	miR-191	expression.	Data	were	analyzed	by	paired	t	test	or	one-way	ANOVA	 followed	 by	 post-hoc	 Holm-Sidak’s	 test	 comparing	 each	 condition	mean	with	the	control	omentum-derived	mean.	*p	˂	0.05;	***p	˂	0.005.	
Supplemental	 Figure	 5.	 α-SMA	 expression	 	 is	 upregulated	 at	 the	 peritoneal	membrane	 in	 peritoneal	 dialysis	 patients.	 Formalin-fixed	 paraffin	 embedded	(FFPE)	 samples	were	 stained	 for	 α-SMA.	 Upper	 panel,	 scale	 bar	 300	 μm;	 Lower	panel,	scale	bar	80	μm.				
Supplemental	 Figure	 6.	 miR-21	 3’UTR	 target	 site	 conservation	 for	 PDZD2,	
S100A10,	 FGF-18,	MATN2	and	 PDCD4	 across	 different	 animals.	 (A-F,	 left	 panel)	Target	sequences	were	acquired	using	TargetScan	and	alignment	was	performed	with	mega	6.	Human	complementary	nucleotide	sequences	and	10	nucleotides	up-	and	down-stream	are	presented.	Conserved	human	complementary	nucleotides	at	the	 seed	binding	 area	 are	displayed	 in	 red	and	whole	nucleotide	 conservation	 is	indicated	with	stars.	(A-F,	right	panel)	mRNA-miRNA	hybrid	was	predicted	using	Diana	 v5.0.	 Seed	 binding	 area	 is	 displayed	 in	 red	 while	 remaining	 nearby	nucleotides	 are	 shown	 in	 black	 (mRNA)	 and	 blue	 (miR-21).	 (A-B)	 PDZD2.	 (C)	
S100A10.	(D)	FGF18.	(E)	MATN2.	(F)	PDCD4.	
Supplemental	 Figure	 7.	miR-31	expression	 in	peritoneal	dialysis	effluent	 (PDE)	from	PD	patients	 (n=230).	RNA	 from	230	PDE	samples	was	 isolated	and	relative	expression	 of	 miR-31	 was	 normalized	 to	 miR-191	 expression.	 Up-regulation	 of	miR-31	expression	in	peritoneal	dialysis	effluent	(PDE)	from	prevalent	PD	patients	compared	 with	 incident	 cases.	 Data	 were	 analyzed	 by	 unpaired,	 Mann-Whitney	test.	Data	represent	the	mean		S.E.M.	from	samples.	*****p	˂	0.0005.	
Supplemental	Figure	8.	Scatter	plot	showing	correlation	of	miR-21	and	potential	mRNA	 targets.	 (A-N)	 Relative	 mRNA	 expression	 in	 control	 omentum-derived	mesothelial	cells	(HPMCs)	–	black	circle,	TGF-β1	treated	(1ng/ml,	48h)	–	light	grey	and	cultured	peritoneal	effluent	derived	(PDE)	cells	with	epithelial	(E)	–	dark	grey	and	non-epithelial	(NE)	–	pale	grey,	phenotype	(n=5	for	each	group).	(A)	NPPB.	(B)	
PDZD2.	(C)	S100A10.	(D)	SASH1.	(E)	TIMP3.	(F)	AIM1L.	(G)	CASKIN1.	(H)	DUSP8.	
(I)	FGF18.	(J)	MATN2.	(K)	NELL2.	(L)	RHOB.	(M)	SPRY1.	(N)	PDCD4.	Target	mRNA	gene	expression	was	analyzed	by	RT-qPCR		and	normalized	to	GAPDH	while	miR-21	was	normalized	to	miR-191.		
Supplemental	Figure	9.	miR-21	target	mRNA	expression	after	miRNA	mimic	(A,	
C,	E,	G,	 I,	K)	or	inhibitor	(B,	D,	F,	H,	 J,	L)	delivery	in	HPMCs	 (A-L)	Target	mRNA	expression	after	48h	of	miRNA	mimic	or	 inhibitor	delivery	 (5	pM,	10	pM	and	20	pM)	 in	 HPMCs.	 miR-control	 mimic	 and	 inhibitor	 –	 white	 bars,	 miR-21	 mimic	 –	black	 bars,	 miR-21	 inhibitor	 –	 grey	 bars.	 (A,	 B)	 SASH1.	 (C,	 D)	 AIM1L.	 (E,	 F)	
CASKIN1.	 (G,	 H)	DUSP8.	 (I,	 J)	NELL2.	 (K,	 L)	 SPRY1.	 Target	 gene	 expression	was	analyzed	 by	 RT-qPCR	 and	 normalized	 to	 GAPDH	 expression	 respectively.	 Data	were	 analyzed	 by	 matched	 factor	 two-way	 ANOVA	 followed	 by	 post-hoc	 Holm-Sidak’s	 test.	 Data	 represent	 the	mean	 S.E.M.	 from	 three	 (miRNA	mimic)	 and	 six	(miRNA	inhibitor)	independent	donor	experiments.	*p	˂	0.05;	**p	˂	0.01.		
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Characteristic 
Patients 
(n=230) 
Age (yr) 54.3±16.2     
Body mass index (kg/m2) 26.5±5.3      
Average Dialysate glucose concentration (%) 1.56±0.38   
4-hour D/P creatinine 0.75±0.15     
Duration of PD (month) 2.85 (1.23, 16.19)       
Albumin (g/L) 34.9±4.9      
Dialysate IL-6 (pg/mL)   3.57 (0.94, 10.44)       
Dialysate IFN-γ (pg/mL) 0.97 (0, 4.49)   
Dialysate IL-1β (pg/mL)  0 (0, 0.072) 
Dialysate TNF-α (pg/mL)  0 (0, 0.20)      
Plasma IL-6 (pg/mL)      1.25 (0.67, 2.49)     
Urine volume  (mL) 904 (292, 1595)  
Comorbidity score 1 (0, 1) 
Icodextrin use (%) 36.30 
Biocompatible solution use  (%)   7.30 
Men (%) 54.30 
APD use (%)        31.20 
Peritonitis count        0 (0, 0) 
 
 
Supplemental Table 1. Study population descriptive characteristics. Data are presented as the mean ± 
SD, median (interquartile range), or as percentage. 
Variable miR-31 miR-21 
miR-21 0.26*** 
 
Age 0.05 0.03 
Body mass index 0.16*  0.15*  
Dialysate glucose  concentration  0.22**  0.04 
4-hour D/P creatinine 0.13 0.16*  
Duration of PD 0.19**  0.13*  
Albumin 0.03 -0.10 
Dialysate IL-6 0.04 0.28*** 
Dialysate IFN-γ 0.09 -0.10 
Dialysate IL-1β 0.00 0.006 
Dialysate TNF-α 0.05 0.04 
Plasma IL-6  0.00 0.11 
Urine volume  -0.24*** -0.19**  
Comorbidity  0.03 0.02 
Icodextrin use  0.00 0.28*** 
Biocompatible solution use 0.08 0.10 
Gender 0.09 -0.02 
Type of PD 0.06 -0.10 
Peritonitis count 0.18**  0.25*** 
Supplemental Table 2. PDE miR-21 correlation with clinically important parameters. * p<0.05, ** 
p<0.01, *** p<0.001  
  
 Variable Coefficient (95% Confidence Interval) p value 
Peritonitis Count 0.052 (0.006, 0.098) 0.028 
miR-21 0.087 (0.038, 0.136) 0.001 
Biocompatible solution usage 0.18 (-0.04, 0.40) 0.114 
Plasma Albumin 0.0096 (-0.001, 0.020) 0.077 
Urine volume -0.00010 (-0.00017, -0.00003) 0.003 
Use of CAPD vs APD 0.14 (0.02, 0.25) 0.023 
 
Supplemental Table 3. Multivariable Regression of miR-31. To understand the relevance of all 
parameters included in Supplemental Table 2 for the described up-regulation of miR-31, multivariable 
linear regression with backwards stepwise variable selection was performed. Stepwise variable 
selection determined a group of tighter risk factors that associated with miR-31 in predicting PD 
outcome that are detailed at the table above. Results for dialysate cytokines and mir-31 are given per 
log order. (n=230).  
 
